Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides

• by Sheng-Guang Li, Yadan Zou, Ji Li, Lina Zhang, Jing Zhang, Ting Long, Ruohan Yu, Yanfeng Zhang

• June 4, 2026

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

• by Kerri Miller

• April 16, 2026

• 3 min

Deep Remission Tied to RA Control

At 5 years, 63% of patients in the CliDR group maintained sustained remission compared with 38% in the non-CliDR group.

• by Andrea Surnit

• May 6, 2026

• 4 min

Multi-Omics Insights into Spondyloarthritis and Psoriatic Arthritis: Integrating Genomics, Transcriptomics, Proteomics, and the Microbiome for Immunological and Clinical Translation

• by Zhu, Minshun , Li, Renzhong , Wu, Sanbing , Chen, Jiaping , Sun, Kui

• April 28, 2026